The first day of the U.S. FDA’s two-day advisory hearing on generative artificial intelligence reflected some of the ...

Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular diseases that can be evident from the ...

With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry giant. The next-generation, oral, ...

Former U.S. FDA Commissioner Margaret Hamburg has added her voice to concerns that the incoming Trump administration’s pledge ...

Ultromics Ltd. received clearance from the U.S. FDA for Echogo Amyloidosis, its artificial intelligence-enhanced software ...

Fat cells from patients who had lost weight after bariatric surgery, as well as from animals who had gained and then lost weight, were transcriptionally distinct from cells that had not experienced ...

Urocortin-2 (UCN2) is a selective corticotropin-releasing factor CRF2 receptor (CRFR2) agonist, which has been previously shown to reduce fat mass while promoting muscle hypertrophy. Hanmi ...

Researchers developed a novel electrochemical biosensor technology capable of assessing symmetric dimethylarginine to detect early kidney disease, which could be adapted to detect other biomarkers for ...

Transposon Therapeutics Inc. has acquired a portfolio of novel nucleoside analogues from Primefour Therapeutics Inc. for the targeted treatment of pancreatic cancer, certain other solid tumors and ...

Startup company Pep2tango Therapeutics Inc., unveiled with backing by Versant Ventures, is advancing unimolecular multireceptor peptide agonists that target GLP-1, GIP, amylin and calcitonin receptors ...

Chiome Bioscience Inc. and Asahi Kasei Pharma Corp. have entered into an exclusive license agreement to develop and commercialize Chiome’s humanized anti-CX3CR1 antibody, PFKR, currently in the ...

The U.S. FDA approved 15 drugs in October, marking a decline from 24 in September and 22 in August. Despite the drop, the 2024 monthly average stands at about 19 approvals, exceeding last year’s ...